Harvard Scientists Develop Groundbreaking “Vagina-on-a-Chip”
Researchers at Harvard University have received recognition for their creation of the world’s first “vagina-on-a-chip,” a pioneering device that utilizes living human cells to simulate female reproductive organs.
This compact, lab-engineered model is expected to provide scientists with enhanced insights into the vaginal microbiome, including its hormonal effects, healthy bacteria, infections, and potential treatments. This method eliminates the need for animal testing, specifically rodents, which lack the same hormonal fluctuations as humans.
Dr. Zore Izadifar, who contributed to the device’s development, expressed to the Post, “These intricate details of human biology can now be observed and tested in ways that were not achievable with animal models. This lays the groundwork for devising better strategies for women’s health.”
Earlier this month, Izadifar was awarded the 2026 Rush Prize in Science, worth £50,000. Experts are hailing this development as a significant leap forward in the often-neglected arena of women’s health.
“For too long, there has been a glaring lack of funding and research focused on women’s health, which has resulted in a lack of understanding regarding diseases that specifically affect women,” she added.
“My goal is to utilize this technology to gain insights into our body’s mechanisms. What enables our bodies to function normally? And what issues place us at higher risk for chronic illnesses?” Izadifar elaborated.
Initially created in 2022, this innovative chip consists of a semi-permeable plastic membrane designed to replicate the vaginal wall’s structure. Scientists will cultivate it with donated human cells from the vagina, allowing the living tissue to develop within the device.
Izadifar explains, “Eventually, these cells mature and form viable tissue that we can conduct tests on. It’s a remarkable step for research.”
About the size of a USB drive, this chip is outfitted with tiny electrical sensors, enabling researchers to monitor how human tissues react to infections, medications, and environmental changes in real time.
The importance of this technology cannot be overstated, as research focused on women’s reproductive health has traditionally relied on animal studies, despite notable biological differences.
“A significant challenge with animal models is that they don’t mirror the hormonal changes experienced by humans,” Izadifar pointed out. “For instance, mice don’t experience menstruation or menopause.”
This distinction complicates the study of issues related to fertility, pregnancy, and infectious diseases.
“Genetically, they are different anatomically. Additionally, their microbiomes do not have the same bacterial populations that humans do,” she noted.
This gap presents challenges for researchers exploring bacterial vaginosis (BV), a prevalent infection caused by bacterial imbalances in the vagina and cervix that impacts over one-quarter of women of reproductive age globally.
“Rats aren’t capable of developing this condition,” Izadifar remarked. “For years, researchers have used mouse models to induce infections artificially, but these animals have more robust immune systems, which allows them to recover from human-like infections much faster.”
Consequently, researchers have found it difficult to test new treatments for BV, which can be treated with antibiotics; however, around 80% of women see a return of symptoms within a year post-treatment.
“Receiving the Rush Prize is a significant recognition for our endeavor to propel human-relevant, non-animal biomedical research forward,” Izadifar remarked.
This annual award is presented by a beauty company in collaboration with a campaign group focused on ethical consumerism.
The Emergence of Organ-on-a-Chip Technologies
The vagina isn’t the first organ to be represented in an on-chip format. Devices have also been created for organs like the lungs, intestines, liver, heart, and eyes.
Last year, a collaborative effort among researchers from Harvard Medical School, Boston Children’s Hospital, and the Wyss Institute led to the development of a “cervix-on-chip” aimed at mimicking the cervix’s structure and function in a similar way to the vaginal chip.
Scientists are optimistic about this technology’s potential to unravel major questions in women’s health.
Initial results from studies using the vaginal chip have been promising. In one investigation, researchers compared the effects of healthy bacteria and those associated with BV on vaginal tissue.
The findings indicated that beneficial lactic acid bacteria help reduce inflammation and maintain proper acidity levels, whereas harmful bacteria linked to BV trigger inflammation and tissue damage.
Dr. Abidemi Junaid, a research scientist at the Wyss Institute and co-author of the study, stated, “It was astonishing to see such contrasting effects from different microbial species on human vaginal cells. Our vaginal chip enabled us to easily observe and quantify these effects.”
“The success of these studies demonstrates that this model is effective for testing various combinations of microorganisms to identify optimal probiotic therapies for BV and other related conditions.”
